UNSPSC 51384526: Ibuprofen lysinate

This classification denotes a cyclooxygenase inhibitor with the molecular formula C13H18O2.C6H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N01ORX9D6S, chemically known as l-lysine, .alpha.-methyl-4-(2-methylpropyl)benzeneacetate (1:1), but more generally known as ibuprofen lysinate, which bears US NIH Compound Identifier 42368. European Medicines Agency schedules ibuprofen lysinate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08098MIG.

Most nations, for tariff purposes, schedule ibuprofen lysinate under HS 29163990. SMILES: CC(C)CC1CCC(CC1)C(C)C(=O)O.C(CCN)C[C@@H](C(=O)O)N.

UNSPSC 51384526 Ibuprofen lysinate is a Commodity code for a specific pharmaceutical ingredient, though state and local procurement activity under this code does not align with its nominal scope. The recent opportunities block contains a single solicitation from Seminole County, Florida for Naloxone and Safe Drug Deactivation Systems — emergency medical and harm-reduction products wholly unrelated to ibuprofen lysinate. State and local governments do not appear to be actively purchasing ibuprofen lysinate as a commodity input through posted solicitations at this time. The code shows little relevant recent activity.

No representative opportunities tied to the actual scope of ibuprofen lysinate procurement are present in the source. Seminole County's IFB60459723LAS, posted June 30, 2026 with response due July 26, 2023, requests 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to the Seminole County Community Health Building in Sanford, Florida — a procurement that does not reflect purchasing patterns under this code. Business development professionals evaluating activity under UNSPSC 51384526 should treat the mismatch as a signal that the code carries limited state and local procurement volume or that the tagging may reflect data-quality issues in the underlying opportunity record rather than actual buying demand for pharmaceutical ingredients.